Dr. Jacob Becraft, a BIO Board member and CEO of Strand Therapeutics, told the House Select Committee on China that China’s accelerated pathway to first‑in‑human trials is creating a competitive advantage for Chinese biotech. In testimony cited by the committee, Becraft said U.S. timelines for first‑in‑human studies often take 2–3 years versus roughly one year in China, and urged policy changes to preserve U.S. competitiveness. Committee remarks cited that nearly half of large pharmaceutical licensing deals in 2025 involved Chinese‑origin molecules, a statistic used to underline shifting industry dynamics. Becraft recommended decentralization, streamlined regulatory processes, and investment in domestic trial capacity to counterbalance China’s gains. The testimony frames clinical‑trial speed as both an economic and national‑security issue and may shape forthcoming legislative or regulatory proposals aimed at clinical‑trial modernization.